LENZ Therapeutics (LENZ) Accumulated Expenses (2020 - 2026)
LENZ Therapeutics (LENZ) reported Accumulated Expenses of $14.9 million for Q1 2026, up 203.12% year-over-year from $4.9 million in Q1 2025, and down 12.59% on a QoQ basis from $17.0 million in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Accumulated Expenses data on file, last reported at $14.9 million in Q1 2026.
- Quarterly Accumulated Expenses rose 203.12% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (up 203.12% YoY) and the FY2025 annual result came in at $17.0 million, up 176.79% from the prior year.
- Accumulated Expenses slipped to $14.9 million in Q1 2026 per LENZ's latest filing, from $17.0 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $17.0 million in Q4 2025 and bottomed at $882000.0 in Q2 2022.
- The 5-year median for Accumulated Expenses is $4.9 million (2024), against an average of $6.8 million.
- The widest annual swing landed in 2022, when Accumulated Expenses jumped 1015.33%; it then tumbled 58.25% in 2025.
- Tracing LENZ's Accumulated Expenses over 5 years: stood at $1.9 million in 2022, then jumped by 584.29% to $12.8 million in 2023, then sank by 51.97% to $6.1 million in 2024, then surged by 176.79% to $17.0 million in 2025, then decreased by 12.59% to $14.9 million in 2026.
- Per Business Quant, the three latest LENZ Accumulated Expenses figures stand at $14.9 million (Q1 2026), $17.0 million (Q4 2025), and $12.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.88 Mn |
| Dec 31, 2025 | 17.02 Mn |
| Sep 30, 2025 | 11.99 Mn |
| Jun 30, 2025 | 7.54 Mn |
| Mar 31, 2025 | 4.91 Mn |
| Dec 31, 2024 | 6.15 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Jun 30, 2024 | 4.18 Mn |
| Mar 31, 2024 | 11.76 Mn |
| Dec 31, 2023 | 12.80 Mn |
| Sep 30, 2023 | 3.42 Mn |
| Jun 30, 2023 | 2.27 Mn |
| Mar 31, 2023 | 7.32 Mn |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 3.35 Mn |
| Jun 30, 2022 | 882,000.00 |
| Mar 31, 2022 | 1.16 Mn |
| Dec 31, 2021 | 886,000.00 |
| Sep 30, 2021 | 300,000.00 |
| Jun 30, 2021 | 723,000.00 |
| Dec 31, 2020 | 126,000.00 |